Please contact us for more information or to learn if you are eligible to participate.
The purpose of this study is to determine if ziltivekimab (administered subcutaneously) reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.
Mahesh Changlani, MD
Novo Nordisk A/S
Type of Trial